Neuphoria Therapeutics Inc. (NEUP) vs PAVmed Inc. (PAVM)
A side-by-side comparison of Neuphoria Therapeutics Inc. and PAVmed Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NEUP
Neuphoria Therapeutics Inc.
$3.46HealthcareDelayed quote: Oct 6, 2026, 2:12 PM EDT
PAVM
PAVmed Inc.
$2.78HealthcareDelayed quote: Oct 6, 2026, 2:15 PM EDT
Total return — NEUP vs PAVM
growth of $100 · dividends reinvested · last 5yNEUP -98.0% (-54.5%/yr)PAVM -99.8% (-71.2%/yr)NEUP compounded faster over this window
Log scale — wide-divergence pair
NEUP PAVM
NEUP vs PAVM: by the numbers
- •NEUP is the larger company ($19M vs $18M market cap).
- •Both run net losses; NEUP's is the smaller (-1578.40% vs -10794.64% net margin).
Metrics side by side
Valuation
| Metric | NEUP | PAVM |
|---|---|---|
| P/S ratio | 15.90 | 158.44 |
| P/B ratio | 0.76 | 0.57 |
Profitability
| Metric | NEUP | PAVM |
|---|---|---|
| Gross margin | 43.54% | -354.93% |
| Operating margin | -835.53% | -30712.68% |
| Net margin | -1578.40% | -10794.64% |
| ROE | -75.34% | -34.50% |
| ROIC | -49.83% | -73.92% |
Growth (annualized)
| Metric | NEUP | PAVM |
|---|---|---|
| Revenue CAGR (5Y) | 11.12% | N/A |
| Total return CAGR (5Y) | N/A | -76.55% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.